Next 10 |
home / stock / stssw / stssw articles
NEW YORK, June 14, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc., (NASDAQ: "STSS" and "STSSW"), an innovative medical device and pharmaceuti...
Signed PO secures first 12 months of syringe product orders against Sharps and Nephron's five-year, $200 million Syringe Sales Agreement. Cur...
InjectEZ acquisition establishing Sharps position in the prefillable syringe (PFS) industry in the U.S. has progressed with the payment of $1 mill...
Sharps will strengthen its manufacturing capacity with a $35 million acquisition of assets, establishing the Company's position in the specia...
Sharps CEO issues letter to shareholders on FDA actions and tariffs affecting Chinese syringes. The FDA began raising quality concerns over Chines...
NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc., (NASDAQ: "STSS" and "STSSW"), an innovative medical device and pharmaceuti...
NEW YORK, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc., (NASDAQ: "STSS" and "STSSW"), an innovative medical device and pharmaceutic...
NEW YORK, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the "Company") (NASDAQ: "STSS" and "STSSW"), an innovative medical device ...
NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the "Company") (NASDAQ: "STSS" and "STSSW"), an innovative medical device ...
News, Short Squeeze, Breakout and More Instantly...
Sharps Technology Inc. Warrant Company Name:
STSSW Stock Symbol:
NASDAQ Market:
NEW YORK, June 17, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. , (NASDAQ: “STSS” and “STSSW”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, has made the first shipment of its 1mL and 3mL ...
NEW YORK, June 14, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. , (NASDAQ: “STSS” and “STSSW”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, is pleased to invite investors to a webinar...
Signed PO secures first 12 months of syringe product orders against Sharps and Nephron’s five-year, $200 million Syringe Sales Agreement. Current Asset Purchase Agreement closing timeline is on track for expected prefillable syringe product shipments to begin by Q2 of 2025. ...